Phaseline

Companies › Cardiff Oncology

Cardiff Oncology: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Onvansertib
Serine/threonine-protein kinase PLK1 inhibitor
PLK1Phase 2Metastatic Colorectal Cancer; Small-cell Lung Cancer; Breast Cancer; Pancreatic CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06106308OnvansertibPhase 2Metastatic Colorectal CancerOncologyNov 2026
NCT05383196OnvansertibPhase 1Breast CancerOncologyDec 2026
NCT06736717OnvansertibPhase 1Pancreatic CancerOncologyJan 2027
NCT05450965OnvansertibPhase 2Small-cell Lung CancerOncologyAug 2027

From the company's SEC filings

Cash and short-term investments of $34m on 2026-06-30; operating cash outflow about $49m a year; runway about 8 months at that burn, to Mar 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PLK1 (1)

Companies with the same targets

SillaJen

Companies built like this

Oncolytics Biotech TuHURA Biosciences Actuate Therapeutics Inhibrx Biosciences Genelux

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.